CMC Biologics, a leading contract manufacturing organization known for its technical excellence in process development and cGMP manufacture, and Innomedica, a life sciences business development company specialized in Japan market, have entered into an agreement to facilitate CMC Biologics’ customer base in the Japan market.
“We view this strategic agreement with Innomedica critical for us to serve our further growing customer base in the second largest healthcare market in the world,” said Gustavo Mahler, Chief Operations Officer of CMC Biologics. “Establishing an in-country commercial presence provides us with the necessary structure to localized services and communications for Japanese biotechnology and pharmaceutical customers for cGMP clinical and commercial production of biopharmaceuticals.”
“We believe CMC Biologics is a great match for Japanese companies looking for premium quality biologics and flexible, committed partner with cGMP facilities in Europe and the USA,” said Anna Kalmi of Innomedica. “CMC has proven capability to carry out projects successfully, raising the clients’ biologics development programs to the next level.”
The Japanese market is the world’s second largest healthcare system totaling $115 billion in biopharmaceutical sales and comprised of global biopharmaceutical leaders including Takeda, Otsuka, Astellas, Daiichi, Sankyo, Eisai and others.With a population of 130 million people with one of the highest GDPs in the world, the country has the fastest aging population of the seven major markets, all Japanese citizens are covered by health insurance, and as a result, high quality and innovative healthcare products are highly valued.
Stacie D. Byars, Global Marketing
Vice President, Business Development